Pharmaceutical OPEX - The Next Generation

Item Type Journal paper
Abstract The history of operational excellence (OPEX) in the pharma industry is short. Since the first serious initiatives were launched at the beginning of the 21st century, OPEX gained momentum and became a priority at all hierarchies in pharma manufacturers all over the world. Simultaneously, the science of pharmaceutical manufacturing appeared on the agenda of the FDA. As a reaction to a continuously rising number of post-approval changes, the FDA started to push the industry toward developing a scientific understanding of pharmaceutical manufacturing processes and encouraged manufacturers to use innovative technologies like PAT (process analytical technology) for better process control. As a result, quality and productivity appeared on the agency's agenda, providing the industry with new opportunities and opening the way for OPEX. The incremental introduction of OPEX in the pharmaceutical industry happened in three major stages. To date, there is no clear-cut definition of the term operational excellence. In fact, the term itself is often used for newly launched improvement activities or as a proxy for cost-cutting programs, Six Sigma, and Lean initiatives, all of which contribute to its dilution over time. OPEX should be understood as the balanced management of cost, quality, and time while at the same time focusing on the customers' needs. To achieve these ends, OPEX comprises structural and behavioral changes thought to optimally support necessary activities. In order to maintain sustainability in changing or volatile environments, OPEX has to be pushed by top management and has to be designed to engage every employee. Obviously, OPEX is not only concerned with performance. It also encompasses the way leading to superior performance and to practices that allow an organization to continuously improve itself.
Authors Friedli, Thomas & Bellm, Daniel
Journal or Publication Title Life Science Leader Magazine
Language English
Subjects business studies
HSG Classification contribution to practical use / society
Refereed No
Date 4 October 2013
Publisher Jameson Publishing
Place of Publication Erie, PA
Volume 2013
Number 10/13: CMO Leadership Awards
Page Range 24-25
Number of Pages 2
Depositing User Prof. Dr. Thomas Friedli
Date Deposited 25 Nov 2013 10:56
Last Modified 20 Jul 2022 17:18
URI: https://www.alexandria.unisg.ch/publications/227570

Download

Full text not available from this repository.

Citation

Friedli, Thomas & Bellm, Daniel (2013) Pharmaceutical OPEX - The Next Generation. Life Science Leader Magazine, 2013 (10/13: CMO Leadership Awards). 24-25.

Statistics

https://www.alexandria.unisg.ch/id/eprint/227570
Edit item Edit item
Feedback?